Thursday 25 Jan/18 at 1:30pm! a QCRI Frontiers of Cancer Research presentation by Dr. Sheela Abraham (DBMS & CBG)
Sheela Abraham, PhD
Assistant Professor, Dept. of Biomedical & Molecular Sciences
Thursday 25 January 2018 at 1:30 pm*
QCRI Conference Rooms 100/101
“Investigating Signalling Pathways in Normal and Cancer Haematopoietic Stem Cells”
Chronic myeloid leukaemia (CML) is a clonal disorder, initiated by the expression of the BCR-ABL1 oncogene. Most CML patients must take tyrosine kinase inhibitors (TKIs) such as imatinib mesylate indefinitely, thus TKIs represent a life-long treatment without providing true cure. Our group identified that in CML the existing residual disease resistant to TKIs, is comprised of leukemic stem cells. To investigate the biology behind this critical tumour-initiating and maintaining subpopulation, we conducted systems approaches providing deeper insight into CML and importantly, engineered a more fundamental synthetic lethality proving superior to single target approaches. Our work has added to the knowledge base surrounding intracellular-based signalling events in leukaemia. In this seminar, I will present previous and future studies that incorporate our ‘OMICS’ approach focused on delineating critical pathways involved in normal and cancer stem cell maintenance.
Host: Dr. Andrew Craig (email@example.com; ext. 32496)
*1:00 pm – Welcome reception for Dr. Abraham, a new recruit in DBMS and Cancer Biology & Genetics division. Please join us for some refreshments (coffee, tea, cookies) and socialize prior to the seminar.
Everyone is welcome!